<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03483324</url>
  </required_header>
  <id_info>
    <org_study_id>AB-110-001</org_study_id>
    <nct_id>NCT03483324</nct_id>
  </id_info>
  <brief_title>Trial of AB-110 in Adults With Hematologic Malignancies Undergoing Cord Blood Transplantation</brief_title>
  <official_title>A Phase 1 Open-Label, Multi-Center Trial of AB-110 in Adults With Hematologic Malignancies Undergoing Cord</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Angiocrine Bioscience</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Angiocrine Bioscience</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase 1b, open label, multi-center trial of AB-110 in adults with hematologic malignancies,
      including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and
      myelodysplasia (MDS) undergoing cord blood transplantation. Subjects will receive
      unmanipulated cord blood (UCB) and AB-110 expanded CD34 enriched hematopoietic progenitor
      cells (HSPC).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 24, 2018</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of adverse events grade 4 or grade 5 as assessed by CTCAEv4</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Graft failure defined as survival to day 42 without absolute neutrophil count greater than or equal to 500/mm3</measure>
    <time_frame>42 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to neutrophil engraftment</measure>
    <time_frame>42 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of sustained donor-derived neutrophil engraftment</measure>
    <time_frame>42 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of sustained donor-derived neutrophil engraftment</measure>
    <time_frame>100 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of sustained donor-derived neutrophil engraftment</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of engraftment syndrome</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of graft failure</measure>
    <time_frame>43 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of graft failure</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of post-transplant phenotype in hematopoietic cells of donor origin</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of grade II - IV acute graft versus host disease (aGVHD)</measure>
    <time_frame>100 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of grade II - IV acute graft versus host disease (GVHD)</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of chronic GVHD</measure>
    <time_frame>100 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of chronic GVHD</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to lymphoid recovery</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of transplant related mortality (TRM)</measure>
    <time_frame>100 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of transplant related mortality (TRM)</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>100 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Free Survival (DFS)</measure>
    <time_frame>100 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Free Survival (DFS)</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Late onset acute GVHD</measure>
    <time_frame>720 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Chronic GVHD</measure>
    <time_frame>720 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Quantitative recovery of T-cells and subsets</measure>
    <time_frame>1 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Quantitative recovery of T-cells and subsets</measure>
    <time_frame>2 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Transplant Related Mortality</measure>
    <time_frame>1 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Transplant Related Mortality</measure>
    <time_frame>2 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Recurrence of malignancy</measure>
    <time_frame>1 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Recurrence of malignancy</measure>
    <time_frame>2 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Disease free survival</measure>
    <time_frame>1 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Disease free survival</measure>
    <time_frame>2 years</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">9</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Acute Lymphoblastic Leukemia in Remission</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Other Acute Leukemias</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Unmanipulated umbilical cord blood plus AB-110</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Unmanipulated Umbilical Cord Blood (UCB)</intervention_name>
    <description>Human leukocyte antigen (HLA) matched umbilical cord blood</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AB-110</intervention_name>
    <description>Expanded cord blood stem cells and engineered human endothelial cells</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have received some immunosuppressive chemotherapy in the preceding 3
             months.

          -  Acute myelogenous leukemia (AML):

               1. Complete first remission (CR1) at high risk for relapse

               2. Complete second remission (CR2).

               3. No documented myelofibrosis at screening marrow biopsy

          -  Acute lymphoblastic leukemia (ALL):

               1. Complete first remission (CR1) at high risk for relapse

               2. Complete second remission (CR2).

          -  Other acute leukemias that are of ambiguous lineage or of other types

          -  Any acute leukemia with marrow aplasia or without adequate count recovery.

          -  Myelodysplastic Syndrome (MDS)

          -  Karnofsky score &gt; 70 %.

          -  Calculated creatinine clearance &gt; 60 ml/min.

          -  Bilirubin &lt; 1.5 mg/dL, ALT &lt; 3 x upper limit of normal

          -  Pulmonary function (FVC, FEV1 and corrected DLCO) &gt; 50% predicted.

          -  Left ventricular ejection fraction &gt; 50%.

          -  Albumin &gt; 3.0 g/dL.

          -  Negative antiviral serology:

          -  Negative human immunodeficiency virus (HIV) antibody.

          -  Negative human T-lymphotropic virus (HTLV)-1 and 2 antibodies.

          -  Negative hepatitis B surface antigen (HBsAg) and undetectable hepatitis B virus (HBV)
             DNA

          -  Negative hepatitis C virus (HCV) antibody or negative HCV ribonucleic acid (RNA)

          -  For female subjects of childbearing potential:

               1. A negative serum pregnancy test

               2. Willing to use contraception throughout the study period.

          -  Male subjects must be willing to use a recommended method of contraception throughout
             the study period, and to refrain from sperm donation throughout the study period.

          -  Two appropriate CB units identified for the subject.

          -  In the judgment of the investigator, participation in the protocol offers an
             acceptable benefit-to-risk ratio when considering current disease status, medical
             condition, and the potential benefits and risks of alternative treatments for the
             subject's cancer.

          -  Willingness and ability to comply with scheduled visits, drug administration plan,
             protocol-specified laboratory tests, other study procedures, and study restrictions.

          -  Evidence of a signed informed written consent

        Exclusion Criteria:

          -  Pregnancy or breastfeeding.

          -  Current active, uncontrolled bacterial, viral, or fungal infection

          -  Prior allogeneic or autologous HCT at any time.

          -  Active malignancy other than the one for which AB-110 transplant is being performed
             within 12 months of enrollment.

          -  Any identified and available 10/10 HLA-matched related donor or 10/10 HLA-matched
             unrelated donor.

          -  Have evidence of recipient donor specific anti-HLA antibodies.

          -  Active central nervous system (CNS) disease at time of screening.

          -  Documented allergy to DMSO, mouse or bovine proteins, or iron.

          -  Subject has other conditions that in the opinion of the investigator would place the
             subject at increased risk for toxicity by participation in the study.

          -  Psychiatric condition making the patient unlikely to comply with protocol therapy,
             required tests and follow-up.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Finegan, MD</last_name>
    <role>Study Director</role>
    <affiliation>Angiocrine Bioscience</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juliet Barker, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shawn Sheeron</last_name>
    <phone>215-796-3286</phone>
    <email>ssheeron@angiocrinebio.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>John Jaskowiak</last_name>
    <phone>408-646-2265</phone>
    <email>jjaskowiak@angiocrinebio.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rie Miyahira</last_name>
      <phone>626-256-4673</phone>
      <phone_ext>80032</phone_ext>
      <email>rmiyahira@coh.org</email>
    </contact>
    <investigator>
      <last_name>Chatchada Karanes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center University of Colorado Anschutz Medical Campus</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Derek Schatz</last_name>
      <phone>720-848-0628</phone>
      <email>derek.schatz@ucdenver.edu</email>
    </contact>
    <investigator>
      <last_name>Jonathan Gutman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Beth Hoover</last_name>
      <phone>646-888-8570</phone>
      <email>hoovere@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Juliet Barker, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2018</study_first_submitted>
  <study_first_submitted_qc>March 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2018</study_first_posted>
  <last_update_submitted>May 17, 2018</last_update_submitted>
  <last_update_submitted_qc>May 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

